Thromboembolic Complications From Atrial Fibrillation and Atrial Flutter in Pediatrics and Young Adults: A Multicenter Study
- 2 December 2024
- journal article
- research article
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (2) , 331-337
Abstract
Background: Atrial fibrillation and atrial flutter are relatively rare in young people and the incidence of thromboembolic complications is unknown. These issues contribute to the limited utility of present guidelines regarding anticoagulation in this population.Objective: To report the number of thromboembolic complications in a cohort of pediatric and young adult patients presenting with atrial fibrillation (AFib) or atrial flutter (AFl) while also assessing anticoagulation practice in a multicenter cohort of young patients with these arrhythmias.Methods: Multicenter, retrospective cohort of patients aged < 25 years old who presented with atrial flutter (AFl) or atrial fibrillation (AFib) between 2000 and 2019 to several large, quaternary pediatric centers, excluding episodes occurring within 30 days of an invasive cardiac procedure.Results: There were 311 episodes of AFib/AFl among 210 patients with a median age of 17 (IQR 14, 20) years. Structural heart disease (SHD) was present in 120 patients (57%) and 20 patients (10%) had a primary cardiomyopathy. Twelve AFib/AFl episodes (8 with AFL, 4 with AFib) were associated with a thrombus, of which 8 (67%) patients had SHD, 2 (17%) had cardiomyopathy and 5 (42%) ventricular dysfunction. The CHADSVASc score was 0–3 for all patients with a thrombus. Of patients with no thrombus at presentation who were cardioverted, 102 (34%) patients were discharged on aspirin and 80 (27%) on anticoagulation. Two patients had symptoms concerning for a thromboembolic event on follow‐up, but none had a newly documented thrombus.Conclusions: Thromboembolic complications occur in children and young adults presenting with AFib/AFl. The majority are associated with SHD, cardiomyopathy, and/or ventricular dysfunction. CHADSVASc was calculated for each patient and was of limited utility. Thromboembolic complications at follow up after cardioversion are rare, and anticoagulation strategies at discharge varied.Keywords
This publication has 17 references indexed in Scilit:
- Anticoagulation management and risk of thromboembolism in healthy youth with atrial fibrillation: Data from a multi-institutional PACES collaborative registryHeart Rhythm, 2022
- Management and outcomes of atrial fibrillation in 241 healthy children and young adults: Revisiting “lone” atrial fibrillation—A multi-institutional PACES collaborative studyHeart Rhythm, 2021
- Long-term outcomes of warfarin versus aspirin after Fontan surgeryThe Journal of Thoracic and Cardiovascular Surgery, 2021
- Thromboembolic events following cardioversion of acute atrial fibrillation and flutter: a systematic review and meta-analysisCanadian Journal of Emergency Medicine, 2021
- 2020 ESC Guidelines for the management of adult congenital heart diseaseEuropean Heart Journal, 2020
- Thromboembolic Risk After Atriopulmonary, Lateral Tunnel, and Extracardiac Conduit Fontan SurgeryJACC, 2019
- Medical and Interventional Outcomes in Pediatric Lone Atrial FibrillationJACC: Clinical Electrophysiology, 2018
- Safety of cardioversion in atrial fibrillation lasting less than 48 h without post-procedural anticoagulation in patients at low cardioembolic riskInternal and Emergency Medicine, 2016
- Anticoagulation, CHA2DS2VASc Score, and Thromboembolic Risk of Cardioversion of Acute Atrial Fibrillation (from the FinCV Study)The American Journal of Cardiology, 2016
- Transthoracic echocardiography for precardioversion screening during atrial flutter/fibrillation in young patientsClinical Cardiology, 2004